glucuronyl glucosamine glycan sulfate (Vessel)

Subscribe to Selected New Research on glucuronyl glucosamine glycan sulfate

22485 relevant articles (609 outcomes, 1465 trials/studies) found for this Bio-Agent

Also Known As:

Vessel; 3 GS; sulodexide; Luzone; 3-glucosaminoglycan sulfate; 3GS; Aterina; Sigma-Tau brand of glucuronyl glucosamine glycan sulfate; Tedec Meiji brand of glucuronyl glucosamine glycan sulfate; Vessel (polysaccharide); glucuronyl glucosaminoglycan sulfate; glucuronylglucosaminoglycan sulfate

Relationship Network

Bio-Agent Context: Research Results

Carbohydrates: 2945

Polysaccharides: 1669

Glycosaminoglycans: 2413

glucuronyl glucosamine glycan sulfate: 22485

Experts

1.	Falk, Ronald J: 10 articles (09/2008 - 09/2003)
2.	Jennette, J Charles: 8 articles (09/2008 - 01/2002)
3.	Hogan, Susan L: 8 articles (09/2008 - 09/2003)
4.	Szczudlik, Andrzej: 7 articles (01/2007 - 01/2002)
5.	Lee, Cheol Whan: 5 articles (03/2008 - 04/2003)
6.	Langford, Carol A: 5 articles (08/2007 - 05/2003)
7.	Hoffman, Gary S: 5 articles (01/2007 - 09/2003)
8.	Turaj, Wojciech: 5 articles (01/2007 - 01/2002)
9.	Nachman, Patrick H: 4 articles (09/2008 - 11/2005)
10.	Chin, Hyunsook: 4 articles (09/2008 - 11/2005)

Related Diseases

1.	Pathologic Constriction (Stenosis) 01/01/1987 - "To establish the most meaningful scoring system, we developed the grading of stenosis which is "critical" or significant in the single-, double-, and triple-vessel method (SDT), and the extent of improvement in the predictive value which may be induced by accounting for the predominance of the three major coronary arteries nourishing the left ventricle. " 05/01/1981 - "In the successfully dilated stenoses or occlusions there was a highly significant increase in the vessel diameter, with a highly significant reduction in the pressure gradient across the stenosis. " 08/01/1979 - "The best results can be expected in patients with single-vessel disease, with a short history of angina (less than 1 year), and with narrow, noncalcified proximal stenosis. " 03/01/1992 - "However, in cases of good collateral circulation, no case showed a complete defect when the target vessel had improved to less than 75% of stenosis. " 03/01/1992 - "In 16 cases of poor collateral circulation, six cases showed a complete defect, although the target vessel had improved to less than 75% of stenosis. " Order ALL the reference details at left...
2.	Neoplasms (Cancer) 05/01/2002 - "When comparing several combinations of vessel characteristics, a combination of any two major characteristics demonstrated the best results (sensitivity, 94% [33 of 39 tumors]; specificity, 93% [three of 45 tumors]). " 07/01/1983 - "DSA was most helpful in demonstrating the presence or absence of major vessel involvement by tumor when this could not be ascertained definitely on CT. " 02/15/2009 - "Immunohistochemical analysis showed a marked decrease in proliferation indices and tumor vessel density in the s.c. " 02/01/2009 - "In addition, curved MPRs or in rare cases 3D reconstructions could be very helpful in identifying the critical anatomic tumor site in the neighbourhood of the visceral vessel system. " 08/01/2007 - "CONCLUSION: The radical resection rate for tumor involving important vessel may be improved with the help of vascular technique." Order ALL the reference details at left...
3.	Thrombosis (Thrombus) 11/15/1996 - "At 90 minutes, patients with TIMI grade 2 flow had greater infarct vessel narrowing and a significantly greater incidence of thrombus than patients with TIMI grade 3 flow. " 07/10/1992 - "Evaluation of 21h and representative analogues in vivo using a rabbit model of small vessel thrombosis revealed significantly greater antithrombotic efficacy compared to that of previously studied compounds with similar intrinsic biological activity measured in vitro but inferior aqueous solubility." 10/01/1978 - "IBC was effective in causing occlusion but resulted in significant inflammatory changes within the thrombus and vessel wall. " 03/01/2002 - "The study suggests that this model using electric vessel stimulation is effective for inducing arterial thrombosis and provides a simple method for recording the dynamic course of thrombus formation." 01/01/1994 - "The greater efficacy of rTAP v rHIR in maintaining vessel patency was also reflected in integrated coronary artery blood flows [91.0(SEM 5.8)% and 84.9(6.1)% of preocclusion flow in rTAP groups v 57.5(12.2)% of preocclusion flow in rHIR group], times to reocclusion [123.3(22.8) and 128.0(6.7) min in rTAP groups v 36.6(23.2) min in rHIR group; p < 0.05], and residual thrombus masses [1.8(0.3) and 2.0(0.3) mg in rTAP groups v 10.4(3.8) mg in rHIR group; p < 0.05]. " Order ALL the reference details at left...
4.	Myocardial Infarction 05/01/2009 - "All the treated vessels (100%) were successfully re-canalized, Trials In Myocardial Infarction (TIMI) score of 3. At 90-day follow-up, of the 5 patients treated, 2 had modified Rankin score (mRS) of < 2. This small series shows the safety and efficacy of the Penumbra System in the thrombolysis of large vessel occlusive disease." 05/01/1993 - "Different thrombolytic regimens for acute myocardial infarction proved to be equally effective in large scale mortality trials despite significant differences in their efficacy with respect to early infarct-related vessel patency as shown in smaller angiographic trials. " 05/01/2009 - "Infarct size, vessel formation and blood perfusion were significantly improved 28 days after myocardial infarction (MI) in FGFR2-Tg, compared with wild-type mice. " 06/06/2006 - "At one-year clinical follow-up (100% of patients), the event-free survival (freedom from death, myocardial infarction, and target vessel revascularization) was significantly improved in the SES group (88% vs. 69%; p < 0.004) as the result of a lower requirement for target vessel revascularization (11% vs. 30%; p < 0.003). " 03/01/2004 - "Statistically significant improvement was noted in late angiographic restenosis (34.7% vs. 76.5%, p <0.0001), target vessel revascularization (14.9% vs. 60.6), and major adverse cardiac events (i.e., death, myocardial infarction, or total vessel revascularization) (17.9% vs. 64.9%, p <0.0001) at 6 months in reference to the nonradiation group. " Order ALL the reference details at left...
5.	Hemorrhage 03/01/1992 - "Terminal vessel embolization was more effective in attaining long-term control of bleeding (15 of 28 patients) than was gastroduodenal artery embolization (eight of 29) (P = .084). " 07/01/2007 - "These results suggest that sulodexide was effective in partially reversing the thrombogenic coagulation profile without increasing the risk of bleeding." 02/01/1998 - "The pressure was recorded when bleeding occurred through the cut end of the vessel or when the pressure reached 300 mm Hg. All three devices were effective in maintaining hemostasis on small (diameter, 0.25-0.5 mm) and medium-sized arteries (diameter, 2-3.5 mm) with a success rate ranging between 75% and 100% (p = n.s.). " 03/01/1992 - "Terminal muscular branch vessel embolization was effective for initial control of bleeding in 27 of 28 cases, and gastroduodenal artery embolization was effective in 25 of 29 (P = .371). " 06/01/2008 - "For selected patients, however, endovascular parent vessel occlusion is usually safe and effective in preventing the progression of symptoms and bleeding." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Heparin (Liquaemin)
2.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
3.	Antineutrophil Cytoplasmic Antibodies (ANCA)
4.	Aspirin (Acetylsalicylic Acid)
5.	Phenobarbital (Luminal)
6.	abciximab (ReoPro)
7.	Sirolimus (Rapamycin)
8.	Calcium
9.	Cholesterol
10.	Nitric Oxide (Nitrogen Monoxide)

Related Therapies and Procedures

1.	Stents
2.	Angioplasty (Angioplasties)
3.	Percutaneous Coronary Transluminal Angioplasty (PTCA)
4.	Transplants (Transplant)
5.	Balloon Angioplasty (Angioplasty, Transluminal)

Best Treatments:
Research Summary Report
on Pathologic Constriction

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 1479 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>